Sumant Kulkarni
Stock Analyst at Canaccord Genuity
(1.24)
# 3,387
Out of 4,784 analysts
116
Total ratings
31.31%
Success rate
-12.48%
Average return
Main Sectors:
Stocks Rated by Sumant Kulkarni
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRVO CervoMed | Maintains: Buy | $12 → $21 | $9.48 | +121.52% | 5 | Mar 18, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $23 → $25 | $7.85 | +218.47% | 6 | Mar 13, 2025 | |
| VYGR Voyager Therapeutics | Maintains: Buy | $14 → $12 | $3.65 | +228.77% | 5 | Mar 13, 2025 | |
| CMPS COMPASS Pathways | Maintains: Buy | $23 → $15 | $2.94 | +410.20% | 3 | Feb 28, 2025 | |
| BIIB Biogen | Maintains: Buy | $298 → $265 | $138.37 | +91.52% | 20 | Feb 13, 2025 | |
| SAGE Sage Therapeutics | Maintains: Hold | $9 → $8 | $8.28 | -3.38% | 5 | Feb 12, 2025 | |
| CYBN Cybin | Maintains: Buy | $86 → $73 | $6.72 | +986.31% | 7 | Feb 12, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $172 → $163 | $113.16 | +44.04% | 14 | Feb 7, 2025 | |
| ITCI Intra-Cellular Therapies | Downgrades: Hold | $119 → $132 | $131.81 | +0.14% | 5 | Jan 31, 2025 | |
| BTAI BioXcel Therapeutics | Maintains: Buy | $112 → $80 | $2.12 | +3,673.58% | 7 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $28 | $11.06 | +153.16% | 4 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 | $1.47 | +648.30% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $86 → $83 | $3.22 | +2,477.64% | 5 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $14 | $6.19 | +126.17% | 1 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $120 → $12 | $5.15 | +133.01% | 4 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $20 | $7.21 | +177.39% | 3 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $26 | $1.65 | +1,475.76% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $33 | $17.07 | +93.32% | 13 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $150 | $27.65 | +442.50% | 4 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $15.08 | - | 2 | Jan 31, 2017 |
CervoMed
Mar 18, 2025
Maintains: Buy
Price Target: $12 → $21
Current: $9.48
Upside: +121.52%
Zevra Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $23 → $25
Current: $7.85
Upside: +218.47%
Voyager Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $14 → $12
Current: $3.65
Upside: +228.77%
COMPASS Pathways
Feb 28, 2025
Maintains: Buy
Price Target: $23 → $15
Current: $2.94
Upside: +410.20%
Biogen
Feb 13, 2025
Maintains: Buy
Price Target: $298 → $265
Current: $138.37
Upside: +91.52%
Sage Therapeutics
Feb 12, 2025
Maintains: Hold
Price Target: $9 → $8
Current: $8.28
Upside: -3.38%
Cybin
Feb 12, 2025
Maintains: Buy
Price Target: $86 → $73
Current: $6.72
Upside: +986.31%
Neurocrine Biosciences
Feb 7, 2025
Maintains: Buy
Price Target: $172 → $163
Current: $113.16
Upside: +44.04%
Intra-Cellular Therapies
Jan 31, 2025
Downgrades: Hold
Price Target: $119 → $132
Current: $131.81
Upside: +0.14%
BioXcel Therapeutics
Jan 6, 2025
Maintains: Buy
Price Target: $112 → $80
Current: $2.12
Upside: +3,673.58%
Nov 18, 2024
Maintains: Buy
Price Target: $31 → $28
Current: $11.06
Upside: +153.16%
Nov 18, 2024
Maintains: Buy
Price Target: $11
Current: $1.47
Upside: +648.30%
Nov 14, 2024
Maintains: Buy
Price Target: $86 → $83
Current: $3.22
Upside: +2,477.64%
Sep 16, 2024
Maintains: Buy
Price Target: $16 → $14
Current: $6.19
Upside: +126.17%
Jun 13, 2024
Downgrades: Hold
Price Target: $120 → $12
Current: $5.15
Upside: +133.01%
May 7, 2024
Maintains: Buy
Price Target: $21 → $20
Current: $7.21
Upside: +177.39%
Apr 30, 2024
Maintains: Buy
Price Target: $36 → $26
Current: $1.65
Upside: +1,475.76%
Mar 12, 2024
Maintains: Buy
Price Target: $40 → $33
Current: $17.07
Upside: +93.32%
Aug 3, 2021
Maintains: Buy
Price Target: $101 → $150
Current: $27.65
Upside: +442.50%
Jan 31, 2017
Upgrades: Buy
Price Target: n/a
Current: $15.08
Upside: -